INTRODUCTION ᴪ
Resistant bacteria are emerging worldwide as a threat to favorable outcome in the treatment of common infections in community and hospital settings 1 . Among the wide array of antibiotics, β-lactams are the most widely used agents. The most common cause of resistance to β-lactam antibiotics is the production of β-lactamases. Emergence of resistance to β-lactam antibiotics began even before ᴪ the first β-lactam, penicillin, was developed. The first plasmid-mediated β-lactamase TEM-1 was originally isolated from blood culture of a patient named Temoniera in Greece, in the early 1960s 2 . TEM-1 being plasmid and transposon mediated has facilitated its spread to other species of bacteria. Another common plasmid-mediated β-lactamase SHV-1 (sulfhydryl variable), is chromosomally encoded in the majority of isolates of K. pneumoniae but is usually plasmid-mediated in E. coli. Over the years, many new β-lactam antibiotics have been developed; however, with each new class of antibiotic, a new β-lactamase emerged that caused resistance to that class of drug. Presumably, the selective pressure imposed by the use and overuse of new antibiotics in the treatment of Copyrighted © by Dr. Arun Kumar Agnihotri. All right reserved patients has resulted in the emergence of new variants of β-lactamase. The introduction of third-generation cephalosporins into clinical practice in the early 1980s was heralded as a major breakthrough in the fight against β-lactamase-mediated bacterial resistance to antibiotics. Soon after the introduction, the first report of plasmid-encoded β-lactamase capable of hydrolyzing the extended-spectrum cephalosporins was published in 1983 from Germany 3 . Hence these new β-lactamases were coined as extendedspectrum β-lactamases (ESBLs This test requires the use of a third-generation cephalosporin antibiotic disc alone and in combination with clavulanic acid. In this study, a disc of Ceftazidime (30µg) alone and a disc of Ceftazidime + Clavulanic acid (30 µg/10 µg) were used. Both the discs were placed at least 25 mm apart, center to center, on a lawn culture of the test isolate on Mueller Hinton Agar (MHA) plate and incubated overnight at 37°C. Difference in zone diameters with and without clavulanic acid was measured. Interpretation: When there is an increase of ≥ 5 mm in inhibition zone diameter around combination disk of Ceftazidime + Clavulanic acid versus the inhibition zone diameter around Ceftazidime disk alone, it confirms ESBL production.
ESBL producing Klebsiella pneumoniae ATCC 700603 was used as the control strain. E-test ESBL strips: Confirmation of ESBL was also done by E-test ESBL strips (AB BIODISK, Solana, Sweden), and the test was performed in accordance with the manufacturer's guidelines. Double ended strips containing gradient of cefotaxime or ceftazidime at one end and cefotaxime or ceftazidime plus clavulanic acid at the other end were tested. The presence of ESBL was confirmed if the ratio of the MIC of cefotaxime or ceftazidime to the MIC of cefotaxime or ceftazidime plus clavulanic acid was ≥ 8.
Statistical analysis
Chi-square test was used with appropriate correction for the observation. Where the cell frequency was less than five, Fisher exact test was applied to see the significance of difference between the resistance levels of various drugs in ESBL producer strains and non-ESBL producer strains using SPSS version15. P ≤ 0.01 was considered significant. (97.53% of isolates were sensitive); while in non-ESBL producing isolates, resistance was nil. ESBL producing isolates were resistant to more antimicrobial agents than non-ESBL producing isolates. The highest rate of resistance in ESBL negative isolates was seen against ampicillin (81.29%) which was significantly (p < 0.01) lower than ESBL producing isolates. This was followed by resistance to ampicillin/sulbactam (78.29%). However, in this case, the difference was not significant (p > 0.05) ( Table 1) . Multidrug resistance was seen in 69.14% ESBLpositive isolates and 21.66% non-ESBL isolates. This difference was highly significant (p < 0.01). . Almost all the ESBL-positive isolates were found to be resistant to Ampicillin and sensitive to Imipenem, which again advocates the usage of carbapenem antibiotics as the therapeutic alternative to β-lactam antibiotics as indicated in many previous studies.
RESULTS

A total of 450 urinary isolates of E.coli
CONCLUSION
The prevalence of ESBL producers at our institute was 60% in accordance to the prevalence reported from other hospitals in India as well as across the globe. Multidrug resistance was significantly (p < 0.01) higher (69%) in ESBL positive isolates than non-ESBL isolates (21%). All the ESBL-positive isolates were found to be sensitive to Imipenem, which again advocates the usage of carbapenem antibiotics. The high level of ESBL prevalence in our set up should ensure regular monitoring and judicious usage of extended-spectrum cephalosporins, periodic surveillance of antibiotic resistance patterns, and efforts to decrease empirical antibiotic therapy. This would go a long way in addressing some of the problems associated with ESBLs. The control measures include judicious use of antibiotics, strict hand-hygiene protocols, and implementation of appropriate infection-control measures in the hospital, especially while treating high-risk patients.
